Rush Medical College, Rush University, 600 S. Paulina Street, Suite 524, Chicago, IL, 60612, USA.
Sackler School of Medicine, Tel Aviv University, Ramat Aviv, P.O.B. 39040, 69978, Tel Aviv, Israel.
J Assist Reprod Genet. 2022 Oct;39(10):2365-2372. doi: 10.1007/s10815-022-02622-w. Epub 2022 Sep 24.
Reproductive medicine has been significantly impacted by the coronavirus (COVID-19) pandemic, and this includes the gestational carrier (GC) process. The objectives of this commentary are to evaluate the impact of COVID-19 on the GC process, as well to communicate Shady Grove Fertility's considerations of and response to COVID-19 on the GC process to the larger assisted reproductive technology (ART) community. We also gathered conclusions drawn from available data on the impact of COVID-19 infection on maternal and neonatal morbidity and mortality as well as on counseling patients on vaccination. We compiled proposals to mitigate risk and to maximize safe evaluation and treatment for GCs during the ongoing pandemic. Over 2 years after the onset of the pandemic, the multiple resurgences of cases in the USA have necessitated nimble strategies to provide ongoing and safe reproductive care and have posed unique challenges to the GC process. With the prospect of the virus continuing to spread globally well into the future, as healthcare professionals of the ART community, we will need to ensure effective collaboration and communication as we provide care during the ongoing pandemic.
生殖医学受到了冠状病毒（COVID-19）大流行的重大影响，包括代孕（GC）过程。本评论的目的是评估 COVID-19 对 GC 过程的影响，并向更大的辅助生殖技术（ART）社区传达 Shady Grove Fertility 对 COVID-19 对 GC 过程的考虑和应对。我们还收集了关于 COVID-19 感染对母婴发病率和死亡率的影响以及对疫苗接种咨询的可用数据得出的结论。我们提出了建议，以减轻风险，并在当前大流行期间最大限度地安全评估和治疗 GC。大流行开始两年多后，美国病例多次反弹，这就需要灵活的策略来提供持续和安全的生殖护理，并对 GC 过程提出了独特的挑战。随着该病毒在未来继续在全球范围内传播，作为 ART 社区的医疗保健专业人员，我们需要在大流行期间提供护理时确保有效的协作和沟通。
